ONO-2808-02:ONO-2808 Phase 1 study

ONO-2808-02:ONO-2808 Phase 1 study Single and multiple oral dose study in healthy adult male subjects, elderly male and female subjects

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071200099

Enrollment

Registered

2021-02-15

Start date

2021-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodegenerative disorder

Interventions

1) Part A: Single Japanese Part A single-dose, dose-escalation, placebo-controlled, double-blind, randomized, parallel-group study in healthy Japanese adult male subjects. 2) Part B (Japanese elderly

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Japanese healthy adult male subjects, Japanese elderly male or female subjects 2) Age at the time of informed consent: 20 to 45 (Healthy adults), 65 to 74 (Elderly males/Elderly females) 3) BMI (at screening): 18.5 kg/m2 to less than 25.0 kg/m2

Exclusion criteria

Exclusion criteria: 1) Subjects who are on a treatment for or with a history of respiratory, cardiovascular, psychiatric, neurologic, gastrointestinal, immunologic, hepatic, renal, hematopoietic or endocrine and/or other disease. 2) Subjects with current or with a history of severe allergy to drugs or foods 3) Subjects with current or with a history of drug or alcohol abuse

Design outcomes

Primary

Measure	Time frame
Safety (All Part), Pharmacokinetic (All Part), Compound concentration in cerebrospinal fluid (Part C only)	—

Contacts

Public ContactCenter Medical

Ono Pharmaceutical Co.,LTD

clinical_trial@ono-pharma.com+81-120626190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026